Latest News
-

AMT-130 at Four Years: Hopeful Signs, Complex Controls
12 min read
uniQure reports that after 4 years, people given high-dose AMT-130 continue to show signs of slower HD progression, providing hope for their recent regulatory submission. But the new analyses are nuanced. We unpack the hopeful, but complex results.
-

Huntington's Disease Therapeutics Conference 2017 – Day 3
5 min read
HDBuzz summarises final day of the 2017 Huntington's Disease Therapeutics Conference in Malta
-

Huntington's Disease Therapeutics Conference 2017 – Day 2
4 min read
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta – day 2
-

Huntington's Disease Therapeutics Conference 2017 – Day 1
6 min read
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta – day 1
-

Enemy at the gates – huntingtin disrupts nuclear transport
7 min read
Two recent studies show how a cellular border control system goes wrong in HD, opening new avenues for HD research.
-

FDA approves a new drug for symptoms of Huntington's disease
4 min read
Deutetrabenazine becomes the first new drug in a decade licensed by the FDA for symptoms of Huntington's disease
-

Weeding out the truth: can cannabis improve Huntington’s?
8 min read
What can individual experiences with cannabis tell us about Huntington's disease?
-

Huntingtin grabs a hammer: DNA repair in HD
8 min read
Huntingtin helps fix damaged DNA, a recent study suggests, under the direction of a gene repair protein called ATM.
-

The benefits of migration, highlighted in Huntington's disease
6 min read
Is HD a developmental disease? HD stops neurons migrating in developing brain, but maybe we can get them going again
-

Treasure your exceptions – using outliers to understand Huntington's disease onset and progression
7 min read
A new study provides the framework for finding factors that affect the onset and progression of HD

